UPLC-MS/PDA检测中药制剂中醋酸泼尼松和醋酸地塞米松的研究

 目的建立快速、准确、高灵敏度的测定中药平喘制剂中醋酸泼尼松和醋酸地塞米松检测的方法。方法采用UPLC-MS/PDA法,以甲醇-0.01mol·L^-1醋酸铵(0.1%甲酸)缓冲溶液梯度洗脱,流速0.2mL·min^-1,离子源为ESI源,正离子检测,对中药制剂中非法添加醋酸泼尼松和醋酸地塞米松进行定性定量分析,并对其裂解途径进行解析。结果6批受试制剂中有2批分别检测到有醋酸泼尼松和醋酸地塞米松。结论此方法选择性强、灵敏度高,可作为分析中药制剂中醋酸泼尼松和醋酸地塞米松的有效检测方法。     

基于PDA的嵌入式ECG监护分析仪

目的为了方便快捷地实时监测心律失常,设计一种基于PDA的嵌入式ECG监护分析仪。方法仪器功能包括低功耗MSP430系列单片机控制心电信号的采集、放大、滤波、转换和在PDA上实时显示、存储和分析,并实现心电数据的远程传输。对仪器工作原理进行分析,把监护分析仪总体结构划分为子模块,并具体介绍各子模块的功能与实现。结果与结论与医院现有的三导全自动心电图机、Holter动态心电图机进行对照,本监护分析仪携带方便、操作简单、接收的心电信号无失真,连续工作时间大于20h等。各高频干扰信号对ECG信号无影响;软件可对心电信号进行实时显示,可连续记录15h的原始心电数据。     

四种小儿动脉导管未闭堵闭术的临床应用:附127例报告

本文采用四种不同的介入治疗方法堵闭动脉导管共127例,成功率海绵塞法为92％(23/25例),双面伞器法为98.6％(66/67例),钮扣式补片法为100％(26/26例),弹簧圈器法为100％(9/9例)。海绵塞法和弹簧圈器无残余分流;术后6个月双面伞器法残余分流为7％(5/67例),钮扣式补片法为15％(4/26例)。钮扣式补片法和弹簧圈器法无并发症,海绵塞法为24％(6/25例),双面伞器法为4％(3/67例)。我们认为,钮扣式补片法及弹簧圈器法在小儿动脉导管未闭的介入治疗中具有较大的应用价值。     

经皮导管介入治疗小儿动脉导管未闭2例分析

目的　应用导管介入性治疗小儿动脉导管未闭 (PDA)并对其近期疗效进行初步评价。方法　 2例 PDA患儿均采用 Amplatzer蘑菇伞法 ,在透视下经 6 F输送器置入 PDA蘑菇伞封堵器 ,术中造影显示 1例PDA蘑菇伞呈管型 ,3.9m m× 7.7m m ,另 1例呈漏斗型 ,18m m× 9.4 mm ,分别选择 14 /12 mm和 16 /14m m PDA蘑菇伞封堵器 ,术后 10 min主动脉弓降部造影 ,4 8h及 3个月、0 .5 a分别行超声心动图 (UCG)检查评价疗效。结果　 2例均一次性放置 PDA蘑菇伞封堵器成功 ,术后随访 0 .5 a,U CG检查动脉水平分流完全消失。结论　应用导管介入治疗小儿 PDA是有效的非手术治疗方法 ,近期疗效满意。     

门诊无线输液管理系统的应用

门诊无线输液系统,实现了输液患者身份准确识别,药物信息准确提取,患者和药物准确匹配,实时呼叫。确保患者输液安全,改善输液秩序,提高护士工作效率,准确统计护士工作量,方便护士绩效考核,合理分配护士资源,提升门诊输液室整体管理水平。     

Critical congenital heart disease screening does not predict car seat tolerance screen outcomes

BackgroundCar Seat Tolerance Screening (CSTS) and Critical Congenital Heart Disease (CCHD) screens were both implemented to identify infants with cardiorespiratory distress. We hypothesized that the CCHD screen would be poorly sensitive to predict a failed CSTS for many reasons.MethodsRetrospective record review of infants in 2013 who qualified for CSTS. Calculated sensitivity, specificity, predictive value (PV) of a failed CCHD screen to identify those infants who failed their CSTS.Results270 subjects underwent both screens and 14 failed a CSTS (5.2%). Of these, 1 failed the CCHD and 1 had an equivocal result. None were diagnosed with CCHD. An abnormal CCHD (failed or equivocal) had a sensitivity = 14.3% and a PV = 40% for predicting CSTS failure.ConclusionsCCHD screening is poorly sensitive and has poor PV for identifying those infants who are at risk of failing a CSTS. We therefore cannot recommend replacement of the CSTS with routine CCHD screening.     

Evaluation of Gianturco Coils for Closure of Large (≥3.5 mm) Patent Ductus Arteriosus

Objectives. This report evaluates the use of Gianturco coils to close large patent ductus arteriosus (PDAs) (≥3.5 mm) and describes transvenous delivery of 0.052-in. (0.132-cm) Gianturco coils.

Background. Coil closure of PDAs has become increasingly popular. However, the technique has significant limitations when used to close large PDAs. This report evaluates patient characteristics, PDA anatomy, hemodynamic variables, delivery technique and coil geometry to determine predictors of success.

Methods. Between January 1995 and January 1997, 16 of 118 patients undergoing catheterization for PDA closure were found to have large PDAs. Their median age and weight were 14 months (range 3 months to 43 years) and 8.5 kg (range 3.5 to 73), respectively. The mean PDA diameter was 4.3 mm (range 3.5 to 5.9). Closure of PDAs was attempted using transcatheter delivery of 0.038-in. (0.096-cm) and 0.052-in. coils. Differences in clinical, anatomic, hemodynamic and technical variables between successes and failures were compared.

Results. Eleven (69%) of 16 patients had successful closure of their PDA. Failures occurred only in patients <8 months of age with an indexed PDA diameter >7 mm/m and a pulmonary/systemic flow ratio ≥2.8:1. Use of 0.052-in. coils tended to reduce the incidence of embolization and the number of coils needed for closure.

Conclusions. Patients >8 months of age can have successful closure of large PDAs with currently available Gianturco coils. The 0.052-in. Gianturco coils can be used safely to close large PDAs in infants as small as 6 kg. Increased experience and improved coil design may improve closure rates of large PDAs in infants.     

Inadvertent stenting of patent ductus arteriosus with Amplatzer Vascular Plug.

We report a 12-month old patient who presented for murmur evaluation after percutaneous closure of type C patent ductus arteriosus (PDA) using a 10 mm Amplatzer Vascular Plug (AGA Medical Corporation, Golden Valley, MN) at an outside institution. Echocardiography revealed a large left-to-right shunt through the implanted device, inadvertently stenting the PDA instead of closing it. The patient underwent repeat catheterization with successful coil implantation within the Amplatzer Vascular Plug, completely eliminating the large residual ductal shunt. Although challenging, this case illustrates the technique of implanting coils within this occlusion device. This case also illustrates that occlusion of type C PDA utilizing the Amplatzer Vascular Plug may not only result in incomplete occlusion but also create a potentially worse clinical situation in which the PDA is stretched larger and stented open. Without consideration of simultaneous coil implantation within this device, use of the Amplatzer Vascular Plug might be contraindicated in type C PDA, because there may be no way to ensure successful closure by the Vascular Plug alone.